FEED the BULL

Welcome to Feed the Bull - A home for investment information and interaction.

Tag: NASDAQ:SONE

Sort
E.g., 2013-05-19
E.g., 2013-05-19
Enter a comma separated list of user names.

S1 Corporation (NASDAQ:SONE) achieved its new 52 week high price of $10.50 where it was opened at $9.84 up 0.06 points or +0.61% by closing at $9.90. SONE transacted shares during the day were over 1.30 million shares however it has an average volume of 1.79 million shares.

Tags:

S1 Corporation (NASDAQ:SONE) achieved its new 52 week high price of $9.88 where it was opened at $9.74 up 0.17 points or +1.76% by closing at $9.84. SONE transacted shares during the day were over 1.63 million shares however it has an average volume of 1.80 million shares.

Read Full Article and Disclaimer at: http://crwewallstreetnewsalert.com/?p=6191

Tags:

S1 Corporation (NASDAQ:SONE) achieved its new 52 week high price of $9.66 where it was opened at $9.57 UP +0.09 points or +0.94% by closing at $9.64. SONE transacted shares during the day were over 1.17 million shares however it has an average volume of 1.73 million shares.

Tags:

** Aruba Networks (ARUN) posted record revenue of $113.8 Million dollars in the fourth quarter 2011, a 47% increase sequentially, while its revenue in fiscal year 2011 grew 49% to $396.5 million dollars compared with Fiscal year 2010.

**************************

** ACI Worldwide, Inc. offered to buy all outstanding shares of S1 Corporation (SONE) for $9.50 a share in a cash-and-stock transaction valued at around $540 million.

******************************

Macatawa Bank Corporation (Nasdaq:MCBC) will commence its previously announced rights offering and public offering of up to 17,826,086 shares of its common stock on May 10, 2011.

Macatawa Bank Corporation common stock is traded on The NASDAQ Global Select Market under the ticker symbol "MCBC."

****

Power3 Medical Products, Inc. (PWRM.OB)

Orofino Gold Corp., (ORFG) recently made public historical exploration findings of its Colombian mining concessions produced by a previous licensee before the eventual forfeiture of that license.

Optimer Pharmaceuticals, Inc. (NASDAQ:OPTR) announced the presentation of information from insurance claims and survey databases highlighting the unmet need for targeted therapies to treat subpopulations at high risk of recurrence of Clostridium difficile infection (CDI). The research also presented the substantial mortality and frequent complications associated with CDI.

Pages

ADVERTISE WITH US